Titan Pharmaceuticals
TTNP

$5.93

1.37%

Market Cap: $5.42M

About: Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

Employees: 4

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

6% more funds holding

Funds holding: 16 [Q1] → 17 (+1) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.75% less ownership

Funds ownership: 4.28% [Q1] → 3.54% (-0.75%) [Q2]

22% less capital invested

Capital invested by funds: $230K [Q1] → $179K (-$50.7K) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for TTNP.

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about TTNP published over the past 30 days

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. – TTNP

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Titan Pharmaceuticals , Inc. ( Nasdaq : TTNP ), relating to its proposed merger with BSKE Ltd. Under the terms of the agreement, Titan shareholders are expected to own approximately 13.3% of the combined company.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. – TTNP

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. - TTNP

NEW YORK , Sept. 4, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Titan Pharmaceuticals, Inc. - TTNP

Shareholder Alert: Ademi LLP investigates whether Titan Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders

MILWAUKEE , Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Titan (NASDAQ: TTNP) for possible breaches of fiduciary duty and other violations of law in its transaction with KE Sdn. Bhd. Click here to learn how to join our investigation https://www.ademilaw.com/case/titan-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Titan Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders

TTNP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Titan Pharmaceuticals, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) and KE Sdn. Bhd. is fair to Titan shareholders. Upon closing of the proposed transaction, Titan shareholders expect to own approximately 13.3% of the combined company. Halper Sadeh encourages Titan shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sade.

TTNP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Titan Pharmaceuticals, Inc. Is Fair to Shareholders

Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”). The Merger Agreement was approved by Titan's board of directors (the “Board”). If the Merger Agreement is approved by the stockholders of Titan and KE (and the other closing conditions are satisfied or waived in accordance with the Merger Agreement), and upon consummation of the transactions contemplated by the Merger Agreement (the “Closing”), Titan will be combined with KE in a “reverse merger” transaction consisting of two steps:

Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.

Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that by letter dated January 24, 2024, the Company was notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum $1.00 bid price requirement and otherwise satisfies all applicable criteria for continued listing on The Nasdaq Capital Market. As such, the listing matter has been closed.

Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria

Titan Pharmaceuticals Announces Reverse Stock Split and Ratio

SOUTH SAN FRANCISCO, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's common stock, which will be effective following the filing of an amendment to the Company's Amended and Restated Certificate of Incorporation (the “Amendment”). The Company's stockholders approved the reverse stock split at a Special Meeting of Stockholders on December 27, 2023. The Company's shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market following the filing of the Amendment, which is intended go effective on January 9, 2024.

Titan Pharmaceuticals Announces Reverse Stock Split and Ratio

See News Rankings